CEO Today - Healthcare Awards 2022

an ambitious and focused external innovation and business development plan to add important new assets to our existing portfolio, with a cumulative firepower of €3 billion over the next four years. We are expanding the scope of our external innovation efforts across all stages of development, including late and early stage deals. Efficiencies are a key part of our financial outlook for 2024 and will support growth with three objectives: invest in the growth of established products; support the launch of new medicines or new indications; and fuel external innovation. Attracting, developing and retaining highly engaged talent is essential, by building on our employees’ strong engagement and supporting their professional development. We nurture a culture of focus and high performance by increasing accountability for faster and better decision-making. In addition, we want to broaden and deepen our expertise as well as fully leverage the collective intelligence of the company. We are accelerating our efforts to truly embrace diversity in all our facets and make Ipsen a more inclusive organization. Our commitment extends to the well-being of all employees, patients, healthcare systems and communities. At Ipsen, we’re dedicated to improving people’s lives and health outcomes. Our 4,500 employees around the world are committed to tackling areas of high unmet medical need to improve the quality of life of patients and caregivers. Ipsen’s vision is to be a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease and neuroscience. Under the overarching theme of Focus. Together. For patients & society, Ipsen is focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society—a strategy for the short and long term. We are working to maximize the value of our core products. Our objective is to take patient-centricity to the next level by truly impacting medical care and patient outcomes in our therapeutic areas, notably by building a deep understanding of the patient journey. Patient insights are essential to challenge the status quo, while collaboration with healthcare systems can bring about advancements for patients around the world. The most promising assets in our portfolio are accelerated and prioritized. We are also executing David Loew CEO of Ipsen Pharma CEO Today Hea l thcare Award s 2022 - FRANCE - - 23 -

RkJQdWJsaXNoZXIy Mjk3Mzkz